W. D. Shrader et al. / Bioorg. Med. Chem. Lett. 22 (2012) 391–395
395
20. Fujisawa, T.; Kariyone, K. Yakugaku Kenkyu 1962, 34, 354.
21. Karrer, P.; Geiger, A. Helv. Chim. Acta 1940, 23, 455.
22. Okugaki, T.; Kasuno, M.; Maeda, K.; Kihara, S. J. Electroanal. Chem. 2010, 639, 67.
23. Webster, R. D. Acc. Chem. Res. 2007, 40, 251.
24. Williams, L. L.; Webster, R. D. J. Am. Chem. Soc. 2004, 126, 12441.
25. Yao, W. W.; Peng, H. M.; Webster, R. D. J. Phys. Chem. C 2009, 113, 21805.
26. Saladino, R.; Neri, V.; Farina, A.; Crestini, C.; Nencioni, L.; Palamara, A. T. Adv.
Synth. Catal. 2008, 350, 321.
these assays. Additionally both compounds work through
a
concerted enzymatic mechanism, as evidenced by the sigmoidal
nature of the EC50 curves. This is further consistent with a
quinone-target43,44 and not a chroman-based radical-scavenging
mechanism.45 Preliminary clinical data has been reported that
a-
tocopherol quinone is effective in treating neurological symptoms
associated with Friedreich’s ataxia.46
27. Kohar, I.; Southwell-Keely, P. T. Redox Rep. 2002, 7, 251.
28. Durckheimer, W.; Cohen, L. A. J. Am. Chem. Soc. 1964, 86, 4388.
29. Jutiviboonsuk, A.; Zhang, H.-J.; Kondratyuk, T. P.; Herunsalee, A.; Chaukul, W.;
Pezzuto, J. M.; Fong, H. H. S.; Bunyapraphatsara, N. Pharm. Biol. (Philadelphia,
PA, U.S.) 2007, 45, 185.
30. De, P. T. J.; Urones, J. G.; Sanchez, M. I.; Fernandez, F. J.; Lithgow, B. A. M.;
Basabe, B. P. Phytochemistry 1987, 26, 1481.
We are actively investigating the enzymatic system responsible
for the conversion of
a-tocopherol to a-tocopherol quinone and
have tentatively named this enzyme—tocooxidohydrolase, connot-
ing the required oxidation and hydrolysis to mediate this conver-
sion. We are pursuing the hypothesis that
a-tocopherol may in
31. Huebscher, J.; Barner, R. Helv. Chim. Acta 1990, 73, 1068.
fact be a pro-vitamin and that deficiency syndromes associated
with the putative tocooxidohydrolase may be in part responsible
for diseases of neurodegeneration and aging.
32. Takano, S.; Sugihara, T.; Ogasawara, K. Synlett 1990, 451.
33. John, W.; Dietzel, E.; Emte, W. Z. Physiol. Chem. 1939, 257, 173.
34. Campuzano, V.; Montermini, L.; Molto, M. D.; Pianese, L.; Cossee, M.;
Cavalcanti, F.; Monros, E.; Rodius, F.; Duclos, F.; Monticelli, A.; Zara, F.;
Canizares, J.; Koutnikova, H.; Bidichandani, S. I.; Gellera, C.; Brice, A.; Trouillas,
P.; DeMichele, G.; Filla, A.; DeFrutos, R.; Palau, F.; Patel, P. I.; DiDonato, S.;
Mandel, J. L.; Cocozza, S.; Koenig, M.; Pandolfo, M. Science 1996, 271, 1423.
35. Mariotti, C.; Solari, A.; Torta, D.; Marano, L.; Fiorentini, C.; Di Donato, S.
Neurology 2003, 60, 1676.
36. Assay details: Primary fibroblasts of similar passage (wild type (WT) and FRDA)
were plated at the same cell density in a 96-well plate on the same day. Dose
response for each compound was computed in the range between 1000 nM
and 1 nM. To maximize potential compound effects, cells were pretreated with
Acknowledgments
We thank the NIH RAID team and the Friedreich’s ataxia re-
search alliance (FARA) for funding and guidance on the preclinical
development of ATQ.
compound 12 h prior to the BSO insult (100 lM). Cell death began between 36
and 48 h after the addition of BSO. Cell viability was measured with Calcein-
AM. Control cells (WT) are not affected by BSO treatment, while FRDA
References and notes
1. Evans, H. M.; Bishop, K. S. Science 1922, 56, 650.
fibroblasts die within 48 h. Each plate contained
a positive and negative
2. Evans, H. M.; Emerson, O. H.; Emerson, G. A.; Smith, L. I.; Ungnade, H. E.;
Prichard, W. W.; Austin, F. L.; Hoehn, H. H.; Opie, J. W.; Wawzonek, S. J. Org.
Chem. 1939, 4, 376.
3. Kohar, I.; Baca, M.; Suarna, C.; Stocker, R.; Southwellkeely, P. T. Free Radical Biol.
Med. 1995, 19, 197.
4. Wu, J. H.; Croft, K. D. Mol. Aspects Med. 2007, 28, 437.
5. Cornwell, D. G.; Ma, J. In Vitamins & Hormones; Gerald, L., Ed.; Academic Press,
2007; Vol. 76, p 99.
control. Compound activity is measure as percent of maximal survival as
observed in vehicle control wells. To avoid plat effects, the outer wells of each
plate are excluded form experimentation.
37. All pharmacokinetic parameters were determined using WinNonLin
Professional, Version 5.3; Pharsight Corporation, Mountain View, CA.
38. Ball, G. F. M. Vitamins—Their Role in The Human Body; Blackwell Publishing,
2004.
39. Ouahchi, K.; Arita, M.; Kayden, H.; Hentati, F.; Benhamida, M.; Sokol, R.; Arai,
H.; Inoue, K.; Mandel, J. L.; Koenig, M. Nat. Genet. 1995, 9, 141.
40. Benomar, A.; Yahyaoui, M.; Meggouh, F.; Bouhouche, A.; Boutchich, M.;
Bouslam, N.; Zaim, A.; Schmitt, M.; Belaidi, H.; Ouazzani, R.; Chkili, T.;
Koenig, M. J. Neurol. Sci. 2002, 198, 25.
41. Sharp, D.; Blinderman, L.; Combs, K. A.; Kienzle, B.; Ricci, B.; Wagersmith, K.;
Gil, C. M.; Turck, C. W.; Bouma, M. E.; Rader, D. J.; Aggerbeck, L. P.; Gregg, R. E.;
Gordon, D. A.; Wetterau, J. R. Nature 1993, 365, 65.
42. Lynch, D.; Willi, S.; Cotticelli, G.; Brigatti, K.; Deutsch, E.; Kucherek, O.; Shrader,
W.; Rioux, P.; Miller, G.; Hawi, A.; Sciascia, T. In American Neurological
Association - 136th Annual Meeting: San Diego, California, USA, 2011; Vol.
Abstract 33 Poster # M1011.
43. Faig, M.; Bianchet, M. A.; Talalay, P.; Chen, S.; Winski, S.; Ross, D.; Amzel, L. M.
Proc. Natl. Acad. Sci. U. S. A. 2000, 97, 3177.
44. Siegel, D.; Bolton, E. M.; Burr, J. A.; Liebler, D. C.; Ross, D. Mol. Pharmacol. 1997,
52, 300.
45. Buettner, G. R. Arch. Biochem. Biophys. 1993, 300, 535.
2011 ‘Edison Announces Results of EPI-A0001 Phase 2A Double Blind Placebo
Controlled 28-day Clinical Trial in the Mitochondrial Disease—Friedreich’s
Ataxia’
6. Monsen, E. R. J. Am. Diet. Assoc. 2000, 100, 1008.
7. Sen, C. K.; Khanna, S.; Roy, S.; Packer, L. J. Biol. Chem. 2000, 275, 13049.
8. Packer, L.; Weber, S. U.; Rimbach, G. J. Nutr. 2001, 131, 369S.
9. Christen, S.; Woodall, A. A.; Shigenaga, M. K.; SouthwellKeely, P. T.; Duncan, M.
W.; Ames, B. N. Proc. Natl. Acad. Sci. U.S.A. 1997, 94, 3217.
10. Shrader, W. D.; Amagata, A.; Barnes, A.; Enns, G. M.; Hinman, A.; Jankowski, O.;
Kheifets, V.; Komatsuzaki, R.; Lee, E.; Mollard, P.; Murase, K.; Sadun, A. A.;
Thoolen, M.; Wesson, K.; Miller, G. Bioorg. Med. Chem. Lett. 2011, 21, 3693.
11. Hensley, K.; Benaksas, E. J.; Bolli, R.; Comp, P.; Grammas, P.; Hamdheydari, L.;
Mou, S. Y.; Pye, Q. N.; Stoddard, M. F.; Wallis, G.; Williamson, K. S.; West, M.;
Wechter, W. J.; Floyd, R. A. Free Radical Biol. Med. 2004, 36, 1.
12. Niki, E. Redox Rep. 2007, 12, 204.
13. Csallany, A. S.; Draper, H. H.; Shah, S. N. Arch. Biochem. Biophys. 1962, 98, 142.
14. Cornwell, D. G.; Ma, J. Y. In Vitamin E: Vitamins and Hormones Advances in Research
and Applications; Elsevier Academic Press: San Diego, 2007; Vol. 76, p 99.
15. Gille, L.; Staniek, K.; Rosenau, T.; Duvigneau, J. C.; Kozlov, A. V. Mol. Nutr. Food
Res. 2010, 54, 601.
16. Nowicka, B.; Kruk, J. Biochim. Biophys. Acta (BBA)—Bioenerg. 2010, 1797, 1587.
17. Evans, H. M.; Emerson, G. A.; Emerson, O. H. Science 1938, 88, 38.
18. Emerson, O. H.; Emerson, G. A.; Evans, H. M. J. Biol. Chem. 1939, 131, 409.
19. Mizuguchi, E.; Achiwa, K. Tetrahedron: Asymmetry 1993, 4, 2303.